CN103929960B - 作为组蛋白脱甲基酶抑制剂的取代的(e)-n’-(1-苯基亚乙基)苯甲酰肼类似物 - Google Patents

作为组蛋白脱甲基酶抑制剂的取代的(e)-n’-(1-苯基亚乙基)苯甲酰肼类似物 Download PDF

Info

Publication number
CN103929960B
CN103929960B CN201280050736.9A CN201280050736A CN103929960B CN 103929960 B CN103929960 B CN 103929960B CN 201280050736 A CN201280050736 A CN 201280050736A CN 103929960 B CN103929960 B CN 103929960B
Authority
CN
China
Prior art keywords
compound
compounds
further aspect
cancer
mao
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280050736.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103929960A (zh
Inventor
哈里普拉萨德·梵卡亚拉帕提
文卡塔斯瓦米·索尔那
史蒂夫·L·华纳
大卫·J·比尔斯
苏尼尔·沙玛
布雷特·史蒂芬斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of CN103929960A publication Critical patent/CN103929960A/zh
Application granted granted Critical
Publication of CN103929960B publication Critical patent/CN103929960B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
CN201280050736.9A 2011-08-15 2012-08-15 作为组蛋白脱甲基酶抑制剂的取代的(e)-n’-(1-苯基亚乙基)苯甲酰肼类似物 Active CN103929960B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161523801P 2011-08-15 2011-08-15
US61/523,801 2011-08-15
PCT/US2012/050948 WO2013025805A1 (en) 2011-08-15 2012-08-15 Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors

Publications (2)

Publication Number Publication Date
CN103929960A CN103929960A (zh) 2014-07-16
CN103929960B true CN103929960B (zh) 2016-08-17

Family

ID=47715455

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280050736.9A Active CN103929960B (zh) 2011-08-15 2012-08-15 作为组蛋白脱甲基酶抑制剂的取代的(e)-n’-(1-苯基亚乙基)苯甲酰肼类似物

Country Status (26)

Country Link
US (2) US8987335B2 (https=)
EP (1) EP2744330B1 (https=)
JP (1) JP6122006B2 (https=)
KR (1) KR101983537B1 (https=)
CN (1) CN103929960B (https=)
AU (1) AU2012296639B2 (https=)
BR (1) BR112014003382B1 (https=)
CA (1) CA2843609C (https=)
CY (1) CY1123345T1 (https=)
DK (1) DK2744330T3 (https=)
EA (1) EA026389B1 (https=)
ES (1) ES2821548T3 (https=)
HK (1) HK1200052A1 (https=)
HR (1) HRP20201433T1 (https=)
HU (1) HUE050962T2 (https=)
IL (1) IL230728A (https=)
IN (1) IN2014CN00961A (https=)
LT (1) LT2744330T (https=)
MX (1) MX356486B (https=)
PL (1) PL2744330T3 (https=)
PT (1) PT2744330T (https=)
SG (1) SG2014009609A (https=)
SI (1) SI2744330T1 (https=)
SM (1) SMT202000551T1 (https=)
WO (1) WO2013025805A1 (https=)
ZA (1) ZA201400881B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109793742A (zh) * 2019-03-04 2019-05-24 四川大学华西医院 一种药物化合物应用

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
RS55764B1 (sr) 2012-10-02 2017-07-31 Gilead Sciences Inhibitori histonskih demetilaza
CA2901022C (en) * 2013-02-27 2021-05-04 Epitherapeutics Aps Substituted pyridine compounds as inhibitors of histone demethylases
JP6320506B2 (ja) * 2013-03-12 2018-05-09 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
NZ715331A (en) 2013-06-19 2019-09-27 The Univ Of Utah Research Foundation Substituted (e)-n’-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
WO2015153516A1 (en) 2014-04-04 2015-10-08 University Of Florida Research Foundation Hdac inhibitor compounds and methods of treatment
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
EP2993175A1 (en) 2014-09-05 2016-03-09 IEO - Istituto Europeo di Oncologia Srl Thienopyrroles as histone demethylase inhibitors
CN106146361A (zh) * 2015-03-16 2016-11-23 四川大学 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
CA2987876A1 (en) 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
JP6999574B2 (ja) * 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
EP3487490A4 (en) * 2016-07-19 2020-01-15 The General Hospital Corporation TARGETING COMPOUNDS OF CANCER STEM CELLS
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
WO2018083138A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US20200069677A1 (en) 2016-12-09 2020-03-05 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
CN106831489B (zh) * 2017-03-23 2018-04-17 郑州大学 苯环丙胺酰腙类化合物、制备方法及其应用
MX2020001323A (es) 2017-08-03 2020-03-20 Oryzon Genomics Sa Metodos para tratar alteraciones del comportamiento.
ES2986559T3 (es) 2017-08-18 2024-11-11 St Europeo Di Oncologia S R L Derivados de indol como inhibidores de la histona desmetilasa
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN109758442B (zh) * 2019-03-20 2021-08-17 武汉大学 二芳基酰肼类化合物在制备抗流感病毒药物中的应用
ES3053813T3 (en) 2019-03-20 2026-01-26 Oryzon Genomics Sa Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
CN114341366A (zh) 2019-07-05 2022-04-12 奥莱松基因组股份有限公司 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法
WO2022020804A1 (en) * 2020-07-24 2022-01-27 Salarius Pharmaceuticals Llc Methods of inhibiting lysine-specific demethylase 1 (lsd-1)
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
JP2024513260A (ja) 2021-04-08 2024-03-22 オリゾン ジェノミックス ソシエダッド アノニマ 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法
CN119546292A (zh) 2022-05-09 2025-02-28 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗恶性周围神经鞘瘤(mpnst)的方法
CN116077661B (zh) * 2022-08-22 2024-09-27 沈阳药科大学 Kdm1a抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083316A2 (en) * 2009-01-14 2010-07-22 Dow Agrosciences Llc Fungicidal compositions including hydrazone derivatives and copper
CN102036967A (zh) * 2008-03-18 2011-04-27 雅培卫生保健产品有限责任公司 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110963A1 (en) * 2001-01-22 2004-06-10 Kaspar Burri Novel hydrazones
JP2002302472A (ja) * 2001-01-31 2002-10-18 Meiji Seika Kaisha Ltd メイラード反応阻害剤
RU2006104697A (ru) 2003-07-16 2006-06-27 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. (Jp) Лекарственное средство для лечения пигментации кожи
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
TW200800145A (en) * 2005-08-26 2008-01-01 Dekk Tec Inc Hydrazone agents to treat cutaneous lesions
US20070207093A1 (en) 2005-11-03 2007-09-06 Linquagen Corp. Hydrazone derivatives and uses thereof
US8338464B2 (en) 2006-11-30 2012-12-25 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of BCL6
JP2010518008A (ja) 2007-02-02 2010-05-27 レッドポイント バイオ コーポレイション インスリンおよびｇｌｐ−１の放出を調節するｔｒｐｍ５阻害物質
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
WO2009027349A2 (en) * 2007-08-24 2009-03-05 Oryzon Genomics Sa Treatment and prevention of neurodegenerative diseases
WO2010003023A2 (en) 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
CA2727890A1 (en) * 2010-01-13 2011-07-13 Norbert Kartner Compounds, compositions and treatments for v-atpase related diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036967A (zh) * 2008-03-18 2011-04-27 雅培卫生保健产品有限责任公司 作为5-ht6拮抗剂的芳基磺酰基吡唑啉甲脒衍生物
WO2010083316A2 (en) * 2009-01-14 2010-07-22 Dow Agrosciences Llc Fungicidal compositions including hydrazone derivatives and copper
WO2010083307A2 (en) * 2009-01-14 2010-07-22 Dow Agrosciences Llc Synergistic fungicidal compositions including hydrazone derivatives and copper

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109793742A (zh) * 2019-03-04 2019-05-24 四川大学华西医院 一种药物化合物应用

Also Published As

Publication number Publication date
US9555024B2 (en) 2017-01-31
NZ621078A (en) 2015-10-30
KR101983537B1 (ko) 2019-05-29
HK1200052A1 (en) 2015-07-31
HUE050962T2 (hu) 2021-01-28
ES2821548T3 (es) 2021-04-26
WO2013025805A1 (en) 2013-02-21
AU2012296639B2 (en) 2016-06-09
CY1123345T1 (el) 2022-03-24
MX2014001842A (es) 2014-07-24
SG2014009609A (en) 2014-05-29
DK2744330T3 (da) 2020-09-07
EP2744330A4 (en) 2015-03-25
HRP20201433T1 (hr) 2020-12-11
MX356486B (es) 2018-05-30
SMT202000551T1 (it) 2020-11-10
AU2012296639A1 (en) 2014-03-06
BR112014003382A2 (pt) 2017-11-21
PT2744330T (pt) 2020-10-01
EA201490453A1 (ru) 2014-09-30
JP2014527531A (ja) 2014-10-16
BR112014003382B1 (pt) 2022-03-15
KR20140077887A (ko) 2014-06-24
IL230728A (en) 2017-05-29
CA2843609A1 (en) 2013-02-21
IL230728A0 (en) 2014-03-31
JP6122006B2 (ja) 2017-04-26
ZA201400881B (en) 2015-07-29
PL2744330T3 (pl) 2020-12-14
EP2744330A1 (en) 2014-06-25
CA2843609C (en) 2020-12-08
SI2744330T1 (sl) 2020-11-30
CN103929960A (zh) 2014-07-16
US20150150864A1 (en) 2015-06-04
LT2744330T (lt) 2020-10-26
US8987335B2 (en) 2015-03-24
EP2744330B1 (en) 2020-07-15
US20140094445A1 (en) 2014-04-03
EA026389B1 (ru) 2017-04-28
IN2014CN00961A (https=) 2015-04-10

Similar Documents

Publication Publication Date Title
CN103929960B (zh) 作为组蛋白脱甲基酶抑制剂的取代的(e)-n’-(1-苯基亚乙基)苯甲酰肼类似物
KR102288648B1 (ko) 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체
US8703946B2 (en) Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors
US20110166158A1 (en) Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
US9642857B2 (en) Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
NZ621078B2 (en) Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1200052

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1200052

Country of ref document: HK